Form Approved
OMB NO: 0920-0740
EXPIRATION DATE: 05/31/2012
Medical Monitoring Project (MMP)
Medical Record Abstraction Form
2012 Medical History Form (MHF)
VERSION 7.1.0
O
PTIONAL-
FOR LOCAL USE ONLY
M Abstraction MMP Participant ID: Facility ID: (ID of the facility where abstraction is being conducted)
Medical record number:
Patient name:
Patient residence:
Street:
City/County: State:
ZIP code:
Physician name: |
DEPARTMENT OF HEALTH AND
HUMAN SERVICES Centers
for Disease Control & Prevention
M
edical
Monitoring Project (MMP)
Medical Record Abstraction Form
2012 Medical History Form (MHF) v7.1.0
I. ABSTRACTION AND IDENTIFICATION |
||
MMP Participant ID: |
||
Surveillance Period (SP)
SP start date:
(12 months prior to date of interview OR 1st contact attempt if no interview obtained) |
SP end date:
(date of interview OR 1st contact attempt if no interview obtained)
|
|
Medical History Period (MHP)
MHP start date: (date of first HIV care (at any facility) documented in this medical record)
First visit to this facility: (date of first available visit to this facility for HIV care)
MHP end date: (day before the SP start date)
OR
HIV test result)
|
||
Abstraction
Facility ID:
(ID of the facility where abstraction is being conducted)
|
For the medical history period Abstract information on all HIV care documented in the medical records at the “Abstraction Facility” using a single MHF regardless of where the care was actually provided to the patient. |
|
Date of abstraction: Abstractor ID:
Mo.
Day
Year |
||
II. PATIENT DEMOGRAPHICS |
||
Date
of birth:
Mo.
Day
Year
If date of birth is not documented, enter documented age:
Mo.
Year |
||
Most recent height (ft/in) prior to the SP start date:
ft.
inches
|
||
Sex
at birth:
(select
one)
|
||
Gender:
(select
one)
|
II. PATIENT DEMOGRAPHICS cont’d |
|||
Hispanic
or Latino ethnicity:
(select
one)
|
|||
Race:
1 (select
all that are documented) 2
3
4
5
6 |
|||
Country
of birth: 1 (select
one)
2 3
4
|
|||
III. MEDICAL HISTORY FORM SECTIONS - OPTIONAL |
|||
Is there documentation of any of the following prior to the SP start date?
|
|||
|
cell count, HIV viral load, or abnormal ALT (SGPT) or AST (SGOT)
|
||
(PCP) or Mycobacterium avium complex (MAC)
|
|
||
(TB)
|
substance abuse counseling or treatment
|
||
immunizations were given
|
depression
|
||
|
|
||
IV. AIDS DEFINING OPPORTUNISTIC ILLNESSES (AIDS OI) |
|||
Is there documentation that any AIDS defining opportunistic illnesses (AIDS OI) were diagnosed prior to the SP start date?
|
|||
AIDS defining opportunistic illnesses (AIDS OI) prior to the SP start date (select all that are documented and record dates)
|
Date of first diagnosis
|
Date not documented |
|
1 |
|
1 |
|
2 |
|
2 |
|
3 |
|
3 |
|
4 |
|
4 |
|
5 |
|
5 |
IV. AIDS DEFINING OPPORTUNISTIC ILLNESSES (AIDS OI) cont’d |
|||
AIDS defining opportunistic illnesses (AIDS OI) prior to the SP start date (select all that are documented and record dates)
|
Date of first diagnosis
|
Date not documented |
|
6 |
|
6 |
|
7 |
|
7 |
|
8 |
|
8 |
|
9 |
|
9 |
|
10 bronchitis, pneumonitis, or esophagitis |
|
10 |
|
11 |
|
11 |
|
12 |
|
12 |
|
13 |
|
13 |
|
14 |
|
14 |
|
15 |
|
15 |
|
16 |
|
16 |
|
17 Extrapulmonary |
|
17 |
|
18 |
|
18 |
|
19 |
|
19 |
|
20 disseminated or extrapulmonary |
|
20 |
|
21 |
|
21 |
|
22 |
|
22 |
|
23 |
|
23 |
|
24 |
|
24 |
|
25 |
|
25 |
|
26 |
|
26 |
|
V. PROPHYLAXIS |
|||
Is there documentation of prescription for prophylaxis of Pneumocystis jiroveci pneumonia (PCP) prior to the SP start date?
Prescription must be for PCP prophylaxis. Medications include: Bactrim® (Septra, Cotrim, Co-trimoxazole, trimethorprim, sulfamethoxazole) Dapsone® Pentamidine® (pentamidine isothianate) Mepron® or Mepron® Suspension (atovaquone) Clindamycin® (clindamycin hydrochloride) + Primaquine® (primaquine phosphate) Dapsone® + Daraprim® (pyrimethamine) + Folinic Acid
|
Is there documentation of prescription for prophylaxis of Mycobacterium avium complex (MAC) prior to the SP start date?
Prescription must be for MAC prophylaxis. Medications include: Biaxin Filmtab® (clarithromycin) Biaxin Granules® Biaxin XL® Zithromax® Zithromax Single Pack® (azithromycin, azithromycin dihydrate) Mycobutin® (rifabutin)
|
VI. HEPATITIS, TOXOPLASMA, AND TUBERCULOSIS (TB) SCREENING |
||||
Is there documentation of screening for hepatitis A, B, C, Toxoplasma, or tuberculosis (TB) prior to the SP start date?
|
||||
Was hepatitis A screening performed prior to the SP start date? (select one)
1
2
3 |
||||
If “Yes,” what were the results?
Select all that apply OR result not documented
|
||||
|
Date
of 1st
positive test:
|
Which Hepatitis A test(s) was/were positive on this date? (select all that apply)
|
||
|
Date of last negative test:
|
|
||
|
||||
Was hepatitis B screening performed prior to the SP start date? (select one)
1
3 |
||||
If “Yes,” what were the results?
Select all that apply OR result not documented
|
||||
|
Date
of 1st
positive test:
|
Which Hepatitis B test(s) was/were positive on this date? (select all that apply)
|
||
|
Date of last negative test:
|
|
||
|
||||
Was hepatitis C screening performed prior to the SP start date? (select one)
1
3 |
||||
If “Yes,” what were the results?
Select all that apply OR result not documented |
||||
|
Date
of 1st
positive test:
|
Which Hepatitis C test(s) was/were positive on this date? (select all that apply)
|
||
|
Date of last negative test:
|
|
||
|
VI. HEPATITIS, TOXOPLASMA, AND TUBERCULOSIS (TB) SCREENING cont’d |
||||||||
Was Toxoplasma screening performed prior to the SP start date? (select one)
1
2
3
Was there a positive result for the most recent Toxoplasma antibody titer prior to the SP start date? (select one)
1
2
3 |
||||||||
Was screening for tuberculosis (TB) performed prior to the SP start date? (select one)
1
2
3
Date of the most recent tuberculin skin test (TST/PPD/Mantoux) or QuantiFERON test (QFT) prior to the SP start date:
Result of the most recent TST/PPD/Mantoux or QFT prior to the SP start date: (enter one for TST/PPD/Mantoux OR one for QFT) |
||||||||
TST/PPD/Mantoux: (enter OR select one) Result in millimeters:
1
2
3
4
5 |
OR
|
QFT: (select one)
1
2
3
4 |
||||||
VII. HEPATITIS AND PNEUMOCOCCAL IMMUNIZATIONS |
||||||||
Is there documentation of whether or not hepatitis A, B, A and B, or pneumococcal immunizations were given prior to the SP start date?
|
||||||||
Was hepatitis A vaccine (Havrix, Vaqta) given prior to the SP start date? (select one: Yes, No, or Not documented) |
||||||||
1 |
|
Date not documented |
||||||
2 |
_____
|
|
||||||
|
||||||||
|
Reason vaccine not given: (select one) |
|
|
|||||
|
|
Prior vaccination |
|
Patient declined |
||||
|
|
Previously infected |
|
Not documented |
||||
|
|
Other, specify |
_____
|
|
||||
|
|
|||||||
4
|
|
|
VII. HEPATITIS AND PNEUMOCOCCAL IMMUNIZATIONS cont’d |
|
||||||||
Was hepatitis B vaccine (Energix B, Recombivax) given prior to the SP start date? (select one: Yes, No, or Not documented) |
|
||||||||
1 |
|
Date not documented |
|
||||||
2 |
_____
|
|
|
||||||
|
|
||||||||
|
Reason vaccine not given: (select one) |
|
|
|
|||||
|
|
Prior vaccination |
|
Patient declined |
|
||||
|
|
Previously infected |
|
Not documented |
|
||||
|
|
Other, specify |
_____ |
|
|
||||
|
|
|
|||||||
_____
|
|
|
|||||||
4 |
|
||||||||
|
|
|
|||||||
Was combination hepatitis A and B vaccine (Twinrix) given prior to the SP start date? (select one: Yes, No, or Not documented) |
|
|
|||||||
1 |
|
Date not documented |
|
||||||
2 |
_____
|
|
|
||||||
|
|
||||||||
|
Reason vaccine not given: (select one) |
_____
|
|
|
|||||
|
|
Prior vaccination |
|
Patient declined |
|
||||
|
|
Previously infected |
|
Not documented |
|
||||
|
|
Other, specify |
_____
|
|
|
||||
|
|
|
|||||||
|
|
|
|||||||
_____
|
|
|
|||||||
4 |
|
||||||||
|
|
|
|||||||
Was pneumococcal vaccine (Pneumovax 23, Pneu-Immune 23) given prior to the SP start date? (select one Yes, No, or Not documented) |
|
||||||||
1 |
|
Mo.
Year
|
Date not documented |
|
|||||
2 |
|
|
|
||||||
|
Reason vaccine not given: (select one) |
|
|||||||
|
|
Prior vaccination |
|
Patient declined |
|
|
|
||
|
|
|
|
Not documented |
|
||||
|
|
Other, specify |
|
||||||
|
|
|
|||||||
3 |
|
|
VIII. ANTIRETROVIRAL THERAPY (ART) |
||||
Is there documentation of prescription of antiretroviral therapy (ART) prior to the SP start date?
|
||||
Date
of first prescribed antiretroviral medication:
Prescribed antiretroviral medications prior to the SP start date: (select all that are documented) |
||||
1 |
9 |
17 (LPV/RTV, Kaletra, Meltrex) |
25 |
|
2 Agenerase) |
10 |
18 |
26 Aptivus) |
|
3 |
11 Fuzeon) |
19 |
27 |
|
4 |
12 |
20 |
28 |
|
5 |
13 formerly TMC125) |
21 MK-0518) |
29 |
|
6 Prezista) |
14 Lexiva) |
22 |
30 Retrovir) |
|
7 Rescriptor) |
15 |
23 Invirase, Fortovase) |
|
|
8 |
16 |
24 |
|
|
31 Specify: |
||||
3 Specify: |
||||
3 Specify: |
||||
3 Specify: |
||||
IX. LABORATORY TEST RESULTS |
||||
Is there documentation of the first positive HIV test result, or laboratory test results for CD4 cell count, or HIV viral load, prior to the SP start date?
|
||||
Is there documentation of the first positive HIV test result?
|
||||
|
|
|||
Is there documentation of CD4 cell count test results prior to the SP start date?
|
||||
|
Date
of lowest CD4 cell count:
|
|||
Is there documentation of HIV viral load (VL) test results prior to the SP start date?
|
||||
|
|
X. HIV ART RESISTANCE TESTING |
||
Is there documentation of HIV ART resistance testing prior to the SP start date?
|
||
Was genotypic ART resistance testing performed prior to the SP start date? (Select one: Yes, No, or Testing not documented) |
||
|
Select all ART classes documented with resistance and/or possible resistance: |
|
1
|
|
|
2
|
|
|
3
|
|
|
4
|
|
|
5
|
||
6 |
||
7
|
||
Was phenotypic ART resistance testing performed prior to the SP start date? (Select one: Yes, No, or Testing not documented) |
||
|
Select all ART classes documented with resistance and/or intermediate resistance: |
|
1
|
|
|
2
|
|
|
3
|
|
|
4
|
|
|
5
|
||
6 |
||
7
|
||
Was virtual phenotypic ART resistance testing performed prior to the SP start date? (Select one: Yes, No, or Testing not documented) |
||
|
Select all ART classes documented with resistance and/or possible / intermediate resistance reported: |
|
1
|
|
|
2
|
|
|
3
|
|
|
4
|
|
|
5
|
||
6 |
||
7 |
||
XI. SUBSTANCE ABUSE |
||
Is there documentation of reported or suspected alcohol abuse or other non-prescribed use of substances, including counseling or treatment for alcohol and/or substance use/abuse prior to the SP?
|
||
Alcohol Abuse |
||
Is
there documentation of alcohol abuse prior to the SP?
|
||
Other Non-prescribed Use of Substances |
||
Is
there evidence of any injection
substance use (e.g., track marks) documented prior to the SP?
|
XI. SUBSTANCE ABUSE cont’d |
|||||||||
Non-prescribed use of substances documented prior to the SP: (select all that are documented and type of use) |
|||||||||
Substance |
Type of Use (select all that apply OR select Not documented) |
||||||||
Injection |
Non-Injection |
Not documented |
|||||||
1 |
|
|
|
||||||
2 |
|
|
|
||||||
3 |
|
|
|
||||||
4 |
|
|
|
||||||
5 |
|
|
|
||||||
6 |
|
|
|
||||||
7 |
|
|
|
||||||
8 |
|
|
|
||||||
9 |
|
|
|
||||||
10 |
|
|
|
||||||
11 |
|
|
|
||||||
12 |
|
|
|
||||||
13 |
|
|
|
||||||
14 |
|
|
|
||||||
15 |
|
|
|
||||||
16 |
|
|
|
||||||
17 |
|
|
|
||||||
1 Specify: |
|
|
|
||||||
1 Specify: |
|
|
|
||||||
2 Specify: |
|
|
|
||||||
21 |
|
|
|
||||||
XII. MENTAL HEALTH |
|||||||||
Is there documentation of any of the following mental illnesses prior to the SP start date?
|
|||||||||
1 |
Anxiety disorder (General anxiety disorder, GAD) |
3 |
Depression (Major depression, depressive disorder) |
||||||
2 |
Bipolar disorder |
4 |
Psychosis |
O
PTIONAL-
FOR LOCAL USE ONLY
MMP MHF v7.1.0
Abstraction
MMP Participant ID: Facility ID:
(ID of the facility where abstraction is being conducted)
XIII. REMARKS |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Page
File Type | application/msword |
File Title | Medical monitoring project (MMP) |
Author | Rita Morgan |
Last Modified By | Bonds, Constance (CDC/OID/NCHHSTP) |
File Modified | 2012-02-06 |
File Created | 2011-12-16 |